SCHEMBL29948161

SCHEMBL29948161

CCOC(=O)c1cccc(F)c1-c1nc2c(OC)c(C(N)=O)ccc2n1CCn1c(-c2c(F)cccc2C(=O)OCC)nc2c(OC)c(C(N)=O)ccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKN1 Q16512 1/20 0.43
PKN2 Q16513 1/20 0.43
PARP1 P09874 3/20 0.39
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
NPC1 O15118 1/20 0.38
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPT P10636 4/20 0.38
USP2 O75604 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
ALOX15 P16050 1/20 0.36
CYP2C19 P33261 1/20 0.36
MAPK10 P53779 1/20 0.36
PTK2B Q14289 1/20 0.36
NCOA1 Q15788 1/20 0.36
NCOA3 Q9Y6Q9 1/20 0.36
TSHR P16473 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24801168 1.00 PKN1 (0.43) PKN1PKN2PARP1KMT2AMEN1
SCHEMBL24801169 0.89 PKN1 (0.45) PKN1PKN2PARP1PTGER4
SCHEMBL29948229 0.89 PKN1 (0.45) PKN1PKN2PARP1PTGER4
SCHEMBL24801176 0.83 PKN1 (0.41) PKN1PKN2PARP1PTGER4BRD4
SCHEMBL24801179 0.83 PKN1 (0.41) PKN1PKN2PARP1PTGER4BRD4
SCHEMBL29948273 0.83 PKN1 (0.43) PKN1PKN2PARP1PTGER4
SCHEMBL23529310 0.83 PKN1 (0.43) PKN1PKN2PARP1PTGER4
SCHEMBL30043149 0.80 PKN1 (0.47) PKN1PKN2PARP1PTGER4
SCHEMBL25095012 0.80 PKN1 (0.47) PKN1PKN2PARP1PTGER4
SCHEMBL30042626 0.79 PKN1 (0.45) PKN1PKN2PARP1PTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132112-A1 COMPOUNDS CTXT PTY LTD (AU) 2026-05-14 US disclosed
EP-4077318-B1 BENZIMIDAZOLE DIMERS AS MODULATORS OF STING CTXT PTY LTD (AU) 2025-10-15 EP disclosed
US-12415785-B2 Compound modulators of sting CTXT PTY LTD (AU) 2025-09-16 US disclosed
US-20230062932-A1 COMPOUNDS CTXT PTY LTD. (AU) 2023-03-02 US disclosed
WO-2022266711-A1 SUBSTITUTED AMIDOBENZIMIDAZOLE DIMERS AS STING MODULATORS Aculeus Therapeutics Pty Ltd (AU) 2022-12-29 WO disclosed
EP-4077318-A1 COMPOUNDS CTXT PTY LTD (AU) 2022-10-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12415785-B2 Compound modulators of sting STING1, IRF3, MAVS PKN1 2995/4885PKN2 3870/4885PARP1 619/4885
US-20260132112-A1 COMPOUNDS STING1, IRF3, CGAS PKN1 3602/4885PKN2 3792/4885PARP1 927/4885
US-20230062932-A1 COMPOUNDS STING1, IRF3, MAVS PKN1 2987/4885PKN2 3800/4885PARP1 468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.